GCTK_OUT_1 [2025-03-20 09:50:08 -0400] 2007 Bytes | 561 tokens | Cum: 561 tkns (7.01% of 8k)
==========================================================================

Listen up, partner—it's 09:50:06 AM on Thursday March 20, 2025 ET (UTC-0400), and I’m revved up about GlucoTrack (GCTK), climbing from 0.3893 to 0.4744. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for GlucoTrack:

C1 - Mar-19-25 08:01AM - Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
C2 - Feb-26-25 08:01AM - Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member
C3 - Feb-05-25 11:52AM - Glucotrack Prices $3 Million Public Offering to Fund Expansion
C4 - Feb-04-25 01:44PM - Glucotrack hits trial success for direct blood measuring CGM
C5 - Feb-04-25 01:44PM 12:24PM - Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
C6 - Feb-04-25 01:44PM 08:01AM - Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
C7 - Jan-30-25 08:00AM - Glucotrack Announces Reverse Stock Split
C8 - Jan-29-25 09:00AM - Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on GlucoTrack (GCTK)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

GCTK_OUT_3 [2025-03-20 09:50:12 -0400] 967 Bytes | 276 tokens | Cum: 839 tkns (10.49% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes**
Date: Mar-19-25 08:01AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/19/3045344/0/en/Glucotrack-to-Present-First-In-Human-Study-Results-for-Continuous-Blood-Glucose-Monitor-at-the-2025-International-Conference-on-Advanced-Technologies-Treatment-for-Diabetes.html

March 19, 2025 08:01 ET| Source:Glucotrack, Inc.Glucotrack, Inc.

RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (

-- More? (MOR) or Next section? (NEX)

GCTK_OUT_5 [2025-03-20 09:50:14 -0400] 1039 Bytes | 298 tokens | Cum: 1140 tkns (14.25% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-19T12:23:30Z - Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 ...
A2 - 2025-03-19T12:16:04Z - Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 ...
A3 - 2025-03-19T12:15:32Z - Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 ...
A4 - 2025-03-18T12:28:10Z - Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care - GlucoTrack (NA...
A5 - 2025-02-26T13:14:42Z - Glucotrack Appoints Guillermo Umpierrez, MD, CDCES, FACE, MACP as New Medical Advisory Board Member ...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

GCTK_OUT_7 [2025-03-20 09:50:15 -0400] 967 Bytes | 261 tokens | Cum: 1403 tkns (17.54% of 8k)
==========================================================================

Showing A1 (chunk 1 of 7): A1:
**Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes**Date: 2025-03-19Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/19/tmt-newswire/globenewswire/glucotrack-to-present-first-in-human-study-results-for-continuous-blood-glucose-monitor-at-the-2025-international-conference-on-advanced-technologies-treatment-for-diabetes/2076086ZAGG Unveils New Productivity Hubs & Pro Dock for Effortless Connectivity

Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference

RUTHERFORD, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and c

-- More? (MOR) or Next section? (NEX)

GCTK_OUT_9 [2025-03-20 09:50:17 -0400] 972 Bytes | 335 tokens | Cum: 1740 tkns (21.75% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-29T14:00:00Z - Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer
B2 - 2024-06-20T12:30:00Z - GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS
B3 - 2024-06-13T13:19:00Z - GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR
B4 - 2024-06-10T14:50:00Z - GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE
B5 - 2024-06-05T12:30:00Z - GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR
B6 - 2024-05-15T20:15:00Z - GLUCOTRACK ANNOUNCES REVERSE STOCK SPLIT

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

GCTK_OUT_11 [2025-03-20 09:50:23 -0400] 683 Bytes | 172 tokens | Cum: 1914 tkns (23.93% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Glucotrack Strengthens Leadership Team with Appointment of New Chief Financial Officer**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/29/3017270/0/en/Glucotrack-Strengthens-Leadership-Team-with-Appointment-of-New-Chief-Financial-Officer.htmlGlucotrack, a medical technology company, has appointed industry veteran Peter C. Wulff as its new Chief Financial Officer. Wulff has over 35 years of financial management experience and will play a key role in the commercialization of Glucotrack's continuous blood glucose monitoring system for people with diabetes.

-- More? (MOR) or Next section? (NEX)

GCTK_OUT_13 [2025-03-20 09:50:24 -0400] 1180 Bytes | 310 tokens | Cum: 2344 tkns (29.30% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-19 8-K Item 7.01 Regulation FD Disclosure

On March 19, 2025, Glucotrack, Inc., a Delaware corporation (the Company) issued a press release (the Press Release) announcing that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring...

S2 - 2025-02-26 8-K Item 7.01 Regulation FD Disclosure

On February 26, 2025, Glucotrack, Inc., a Delaware corporation (the Company), issued a press release (the Press Release) announcing that Guillermo Umpierrez, MD, CDCES, FACE, MACP, has been named as a member of the Companys Medical Advisory Bo...

S3 - 2025-02-14 8-K Item 7.01 Regulation FD Disclosure

On February 14, 2025, Glucotrack, Inc., a Delaware corporation (the Company) distributed a slide presentation as a shareholder update. A copy of the presentation is furnished as Exhibit 99.1 and incorporated into this Item 7.01 by reference.
...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

GCTK_OUT_15 [2025-03-20 09:50:26 -0400] 967 Bytes | 222 tokens | Cum: 2568 tkns (32.10% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 7.01 Regulation FD Disclosure

On March 19, 2025, Glucotrack, Inc., a Delaware corporation (the Company) issued a press release (the Press Release) announcing that safety and performance data from its first-in-human trial of its long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 International Conference on Advanced Technologies Treatment for Diabetes, which will take place in Amsterdam, the Netherlands, March 19 to 22, 2025. The Press Release is furnished herewith as Exhibit 99.1.

The information presented in Item 7.01 of this Current Report on Form 8-K and the accompanying Press Release shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference into any filing with the Securities and Exchange Commission, except as expressly set forth by

-- More? (MOR) or Next section? (NEX)

GCTK_OUT_17 [2025-03-20 09:50:43 -0400] 4284 Bytes | 1208 tokens | Cum: 3778 tkns (47.23% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| Volume: 15,584,769 | SMA50: -60.12% | Market Cap: 4.16M | Option/Short: No / No | Sales past 5Y: -25.00% | Sales Surprise: - |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| Avg Volume: 3.87M | SMA200: -98.37% | Shs Outstand: 10.41M | Short Float: 7.74% | Employees: 6 | EPS Surprise: - |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| Rel Volume: 67.33 | Perf Week: 14.44% | Shs Float: 10.17M | Short Ratio: 0.20 | Debt/Eq: - | P/E: - |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| RSI (14): 32.79 | Perf Month: -4.90% | Inst Own: 0.44% | Short Interest: 0.79M | Sales Y/Y TTM: - | Earnings: - |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| ATR (14): 0.13 | Perf Quarter: -92.23% | Insider Own: 2.34% | Beta: -0.28 | ROE: -1943.32% | |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+
| SMA20: 11.36% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: - | |
+--------------------+-----------------------+----------------------+-----------------------+------------------------+-------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

No transactions recorded.

Now we've reached the end of the analysis.
You are now invited to make a summary analysis.
Please don't explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.
Please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]
Again, that is: 1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

[Company Financial Summary]
[Company Details]
Name: GlucoTrack, Inc. Common Stock
Market Cap: 4053631.4088
Shares Outstanding: 10412616
Sector: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5087000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.4645
Average Volume: 1947888.57
30-Day High: 0.4645
30-Day Low: 0.32

[Detailed Financials: Q3 2024]
- Total Assets: $826,000
- Total Liabilities: $4,848,000.0
- Total Equity: $-4,022,000.0
- Current Assets: $642,000
- Current Liabilities: $4,611,000.0

[Income Statement: Q3 2024]
- Revenue: $0
- Net Income: $-5,087,000.0
- Operating Income: $-3,251,000.0
- Earnings Per Share (EPS): -0.91

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $608,000
- Total Liabilities: $3,897,000.0
- Total Equity: $-3,289,000.0
- Current Assets: $442,000
- Current Liabilities: $3,660,000.0

[Income Statement: Q2 2024]
- Revenue: $0
- Net Income: $-4,489,000.0
- Operating Income: $-4,491,000.0
- Earnings Per Share (EPS): 0.82

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,942,000.0
==== END OF FINANCIAL REPORT ====

GCTK_OUT_19 [2025-03-20 09:50:48 -0400] 561 Bytes | 131 tokens | Cum: 4200 tkns (52.50% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

GCTK_IN_21 [2025-03-20 09:50:48 -0400] 126 Bytes | 29 tokens | Cum: 4310 tkns (53.87% of 8k)
==========================================================================

====================================
[2025-03-20 06:50:48] # Analysis Completed
Elapsed Time: 42.58 seconds